Sepracor Estorra
Executive Summary
Brand name Estorra for sleep disorders treatment esopiclone selected by Sepracor. An NDA for Estorra, the single isomer version of Aventis' Imovane (zopiclone), is expected by the end of 2001. Sepracor plans to have 1,250 reps in place for a scheduled 2002 launch (1"The Pink Sheet" Dec. 11, 2000, p. 24)
You may also be interested in...
Sepracor Sales Force Expansion To 1,900 Planned For Up To 10 New Products
Sepracor plans to add more than 1,700 sales reps in the next three years to support upcoming product launches, President and COO William O'Shea announced during a Dec. 4 analyst conference.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials